Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2023
Total Revenue
▼$666.7M
Program Spending
83%
of total expenses go to program services
Total Contributions
$56.1M
Total Expenses
▼$623M
Total Assets
$402.7M
Total Liabilities
▼$166.4M
Net Assets
$236.3M
Officer Compensation
→$8M
Other Salaries
$174.9M
Investment Income
$31.1M
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$299M
VA/DoD Award Count
18
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$302.4M
Awards Found
22
Department of Defense
$34.8M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$22.9M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS
Department of Defense
$18M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$17.8M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCES
Department of Defense
$17.5M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCES
Department of Defense
$17.5M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS
Department of Defense
$17.5M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS
Department of Defense
$16.7M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$16.5M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$8.4M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Defense
$2.9M
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE
Department of Health and Human Services
$2.1M
CLINICAL AND MECHANISTIC STUDIES DEFINING OPTIMAL PREPARATIVE APPROACHES TO INFANTS WITH IL2RG/JAK3/RAG1/RAG2 SCID: A RANDOMIZED TRIAL OF BUSULFAN DOSAGE - PROJECT SUMMARY SEVERE COMBINED IMMUNODEFICIENCY (SCID) IS A GROUP OF GENETIC DISORDERS THAT ABROGATE T CELL DEVELOPMENT AND FUNCTION. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS THE STANDARD TREATMENT FOR THE DISEASE AND CAN BE PERFORMED SUCCESSFULLY IN SCID PATIENTS WITHOUT THE HIGH DOSE PRE-HCT BUSULFAN CONDITIONING DUE TO THE UNIQUE CAPACITY FOR PROGENITORS TO ENGRAFT IN THE EMPTY THYMUS AND RECONSTITUTE T CELL DEVELOPMENT. WITHOUT CONDITIONING, LINEAGES OTHER THAN T CELLS REMAIN OF HOST ORIGIN. THE CSIDE PROTOCOL WAS FUNDED WITH AN EARLIER GRANT TO TEST THE EFFICACY AND SAFETY OF A REGIMEN OF LOW DOSE, INDIVIDUALIZED TARGETED BUSULFAN COMPARED TO MODERATE DOSE IN SCID PATIENTS AT RISK OF POOR HUMORAL OUTCOME UNDERGOING NON-MATCHED SIBLING DONOR HCT. WE HYPOTHESIZE THAT PATIENTS RANDOMIZED TO RECEIVE LOW DOSE BUSULFAN WILL ACHIEVE SIMILAR OUTCOMES COMPARED TO THOSE RECEIVING MODERATE DOSE (MYELOABLATIVE) BUSULFAN, ACHIEVING BOTH T AND B CELL IMMUNE RECONSTITUTION. DUE TO COVID AND COMPETITION WITH GENE THERAPY, ACCRUAL SLOWED, BUT WITH 50 CENTERS OPEN AND A REDESIGNED APPROACH, ADDITIONAL ENROLLMENT FACILITATED BY THIS GRANT WILL ENSURE THAT THE TRIAL REACHES MEANINGFUL CONCLUSIONS. IN AIM 1, PATIENTS HAVE BEEN RANDOMIZED TO CUMULATIVE AREA-UNDER-THE-CURVE (CAUC) EXPOSURE OF BUSULFAN OF 30 MG*H/L VERSUS 60 MG*H/L. IL2RG/JAK3 PATIENTS ALSO RECEIVE RATG, WHILE RAG1/2 PATIENTS RECEIVE RATG, FLUDARABINE, AND THIOTEPA. STEM CELL SOURCES INCLUDE UNRELATED AND HAPLOIDENTICAL RELATED DONOR PRODUCTS THAT HAVE BEEN TCRΑΒ+/CD19+ DEPLETED WITH NO POST-HCT GVHD PROPHYLAXIS. THE SAFETY PROFILE OF THE TRIAL HAS BEEN EXCELLENT TO DATE. THE ORIGINAL PRIMARY ENDPOINT WAS PROTECTIVE ANTIBODY RESPONSE TO TETANUS BY 2 YEARS POST-HCT. BECAUSE OF ENROLLMENT CHALLENGES, WE REDESIGNED THE PRIMARY ENDPOINT INTO AN ORDINAL RANKED WIN COMPARISON, WHICH ALLOWS HIGHER POWER EVEN IF WE CANNOT FULLY ENROLL. THE PRIMARY OUTCOME WILL CENTER AROUND THE IL2RG/JAK3 COHORT, WHICH SHOULD ACHIEVE FULL ACCRUAL, RANDOMIZING 32 PATIENTS. THE RAG1/2 COHORT WILL CLOSE ONCE THE IL2RG/JAK3 COHORT CLOSES, LIKELY ACCRUING UP 18-20 PATIENTS WHICH WE WILL ANALYZE DESCRIPTIVELY. IN AIM 2, WE HYPOTHESIZE THAT DONOR HSC ENGRAFTMENT MEASURED BY THE SURROGATE OF MYELOID DONOR CHIMERISM WILL BE ASSOCIATED WITH SUPERIOR QUALITY OF T CELL RECONSTITUTION AND IMPROVED ADAPTIVE IMMUNE RESPONSES TO VACCINATION. WE HYPOTHESIZE THAT T CELL EXHAUSTION AND POOR T CELL RECEPTOR (TRB) DIVERSITY SEEN IN PATIENTS UNDERGOING HCT IN THE ABSENCE OF CONDITIONING WILL BE DIMINISHED OR ABSENT IN CSIDE PARTICIPANTS DUE TO IMPROVEMENTS IN THYMIC OUTPUT ASSOCIATED WITH ENGRAFTMENT OF DONOR-DERIVED HSC. WE HYPOTHESIZE THAT IL2RG/JAK3 PATIENTS RECEIVING MODERATE DOSE BUSULFAN AND/OR WITH HIGH LEVEL DONOR CHIMERISM WILL EXHIBIT MULTIPLE IN VITRO BIOMARKERS OF IL-21 RESPONSE, AS THIS CYTOKINE SIGNALS VIA IL2RG/JAK3. WE HYPOTHESIZE THAT VACCINE RESPONSE WILL CORRELATE WITH NORMALIZATION OF IGH CDR3 DIVERSITY IN RAG1/2 PATIENTS WITH MIXED CHIMERISM DUE TO STRONG SELECTIVE ADVANTAGE FOR ANTIGEN-SPECIFIC B CELLS. WE HYPOTHESIZE THAT T CELL TOLERANCE WILL OCCUR BY DIFFERENT MECHANISMS (CENTRAL DELETION VERSUS PERIPHERAL REGULATION) ACCORDING TO DONOR TYPE. FINALLY, WE HYPOTHESIZE THAT ANALYSIS OF PK SAMPLES FOR ELEMENTS OF OUR PREPARATIVE APPROACHES (RATG, THIOTEPA, AND FLUDARABINE) WILL ALLOW TARGETED TREATMENT OF INFANTS UNDERGOING HCT FOR SCID OR OTHER DISORDERS MOVING FORWARD.
Department of Health and Human Services
$882.9K
"PROMOTING & PROTECTING HEALTHY SURVIVORSHIP FOR TRANSPLANT PATIENTS, FAMILIES &
Department of Defense
$587.5K
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS
Department of Health and Human Services
$349K
BMT CORE - PEDIATRIC TRANSPLANTATION AND CELLULAR THERAPY CONSORTIUM (PTCTC): PROVIDING CLINICAL TRIAL ACCESS FOR CHILDREN WITH LIFE THREATENING DISEASES - ABSTRACT: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS UNIQUELY CURATIVE FOR A VARIETY OF PEDIATRIC MALIGNANT AND NON-MALIGNANT CONDITIONS. WITH RESPECT TO NON-MALIGNANT CONDITIONS, DUE TO THE INCREASING USE OF DNA-BASED SCREENING AND DIAGNOSTIC TESTING, MANY OF THE GENETIC DISEASES THAT ARE CURABLE BY HCT ARE NOW IDENTIFIED EARLY IN LIFE. ACCORDINGLY, ~35% OF ALL PEDIATRIC HCT PROCEDURES ARE PERFORMED FOR NON-MALIGNANT DISEASES, WHICH IS SIGNIFICANTLY HIGHER THAN THE PROPORTION OF NON-MALIGNANT DISEASES FOR WHICH HCT IS PERFORMED FOR ADULTS. HCT APPROACHES DIFFER SIGNIFICANTLY BETWEEN PATIENTS WITH MALIGNANT AND NON-MALIGNANT DISEASES. THOSE WITH MALIGNANT CONDITIONS, IN BOTH CHILDREN AND ADULTS, UNDERGO EXTENSIVE CYTOTOXIC CHEMOTHERAPY CYCLES, LEADING TO A COMPROMISED IMMUNE SYSTEM AND REDUCED CAPACITY TO REJECT DONOR CELLS. IN CONTRAST, PATIENTS WITH NON- MALIGNANT DISEASES, HAVING NOT UNDERGONE PRIOR CHEMOTHERAPY, EXHIBIT A SPECTRUM OF IMMUNE RESPONSES, RANGING FROM ABSENCE TO HYPER-ACTIVATION, DEPENDING ON THE SPECIFIC HEMATOPOIETIC CELL TRANSPLANTATION INDICATION. THUS, A MORE PERSONALIZED HCT APPROACH MAY BENEFIT SUCH PATIENTS. ONE OF THE MAJOR AREAS OF UNMET NEED FOR PERSONALIZED HCT ARISES FROM THE FACT THAT THE METABOLISM OF PRE-HCT CHEMOTHERAPY VARIES SIGNIFICANTLY ACROSS INDIVIDUALS. THIS VARIATION, IN BOTH WEIGHT-BASED AND BODY SURFACE AREA-BASED DOSING, CAN LEAD TO SOME PATIENTS RECEIVING TOO MUCH OR TOO LITTLE CHEMOTHERAPY EXPOSURE, RISKING EITHER TOXICITY OR NON-ENGRAFTMENT. BECAUSE OF THIS, THE IDEAL SITUATION MIGHT BE ONE WHERE PHARMACOKINETIC MODELING COULD BE USED TO MORE ACCURATELY DOSE PATIENTS, WHICH WOULD BETTER BALANCE IMMUNE SUPPRESSION AND TOXICITY. THESE AND MANY OTHER VARIABLES HIGHLIGHT THE UNIQUE NEEDS OF PEDIATRIC HCT RECIPIENTS, MAKING IT A DISTINCT DISCIPLINE WITHIN THE LARGER FIELD OF HCT. FURTHER, AT ANY SINGLE TRANSPLANT CENTER, THE NUMBER OF CHILDREN AND YOUNG ADULTS UNDERGOING HCT IS RELATIVELY SMALL, AND THE DISEASES TREATED ARE DIVERSE, MAKING IT ESSENTIAL FOR CENTERS TO WORK TOGETHER IN A COOPERATIVE GROUP SETTING. FOR >30 YEARS THE PEDIATRIC TRANSPLANTATION AND CELLULAR THERAPY CONSORTIUM (PTCTC) HAS BEEN A PEDIATRIC CLINICAL TRIALS CONSORTIUM FOCUSED ON BRINGING CLINICAL TRIALS TO CHILDREN AND YOUNG ADULTS WITH BOTH MALIGNANT AND NON-MALIGNANT DISEASES. THE PTCTC IS NOW THE LARGEST PEDIATRIC-FOCUSED HCT CONSORTIUM IN THE WORLD. IN THIS PROPOSAL WE DESCRIBE OUR PLANS AND DESIRE TO CONTINUE TO BE A CORE CLINICAL CONSORTIUM (CCC) OF THE BMT CTN. THESE INCLUDE (A) DETAILING OUR UNIQUE CAPABILITIES OF THE PTCTC WITHIN THE BMT CTN; (B) PROPOSING A CLINICAL TRIAL TO OPTIMIZE THE CONDITIONING REGIMEN FOR CHILDREN AND ADULTS WITH INBORN ERRORS OF IMMUNITY (IEI); AND (C) DESCRIBING THE OPERATIONAL AND SCIENTIFIC APPROACH OF THE PTCTC TO HCT TRIALS, AND HOW THIS APPROACH COULD BENEFIT THE BMT CTN. TOGETHER, OUR UNIQUE EXPERTISE, CREATIVITY, COMMITMENT TO DIVERSITY, MENTORSHIP, AND INNOVATIVE CLINICAL TRIALS UNDERSCORES OUR POTENTIAL TO CONTRIBUTE SIGNIFICANTLY TO THE BMT CTN'S OBJECTIVES, AND TO ADVANCE THE HCT FIELD.
Department of Health and Human Services
$10K
STEM CELL TRANSPLANTATION IN 2020: A WORKFORCE AND INFRASTRUCTURE ASSESSMENT
Source: Federal Audit Clearinghouse (fac.gov)
Total Audits
10
Clean Audits
10
Material Weakness
No
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditure | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2025 | Clean | Unmodified (Clean) | $27.4M | Yes | 2026-01-30 |
| 2024 | Clean | Unmodified (Clean) | $50.3M | Yes | 2025-02-21 |
| 2023 | Clean | Unmodified (Clean) | $55.4M | Yes | 2024-02-23 |
| 2022 | Clean | Unmodified (Clean) | $57.9M | Yes | 2023-01-26 |
| 2021 | Clean | Unmodified (Clean) | $47.6M | Yes | 2022-02-03 |
| 2020 | Clean | Unmodified (Clean) | $46.7M | Yes | 2021-02-04 |
| 2019 | Clean | Unmodified (Clean) | $48.1M | Yes | 2020-02-03 |
| 2018 | Clean | Unmodified (Clean) | $43.9M | Yes | 2019-01-21 |
| 2017 | Clean | Unmodified (Clean) | $42.1M | Yes | 2018-01-24 |
| 2016 | Clean | Unmodified (Clean) | $41.7M | Yes | 2017-01-29 |
Financial Report
Unmodified (Clean)
Federal Expenditure
$27.4M
Financial Report
Unmodified (Clean)
Federal Expenditure
$50.3M
Financial Report
Unmodified (Clean)
Federal Expenditure
$55.4M
Financial Report
Unmodified (Clean)
Federal Expenditure
$57.9M
Financial Report
Unmodified (Clean)
Federal Expenditure
$47.6M
Financial Report
Unmodified (Clean)
Federal Expenditure
$46.7M
Financial Report
Unmodified (Clean)
Federal Expenditure
$48.1M
Financial Report
Unmodified (Clean)
Federal Expenditure
$43.9M
Financial Report
Unmodified (Clean)
Federal Expenditure
$42.1M
Financial Report
Unmodified (Clean)
Federal Expenditure
$41.7M
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023IRS e-File | $666.7M | $56.1M | $623M | $402.7M | $236.3M |
| 2022IRS e-File | $578M | $59.6M | $571.2M | $352.3M | $197.5M |
| 2021 | $445.1M | $51.2M | $465.5M | $364.8M | $225.3M |
| 2020 | $443M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Amy Ronneberg | Chief Executive Officer | 48 | $1.5M | $0 | $455K | $2M |
| Steven Devine | Chief Medical Officer | 50 | $900.4K | $0 | $219.5K | $1.1M |
| Krista Dusil | Chief Financial Officer (thru 2/24) | 49 | $649.8K | $0 | $53.2K | $703K |
| Katherine Heyerdahl | Chief Financial Officer (began 4/24) | 48 | $0 | $0 | $0 | $0 |
| Brian Reithel | Chair | 1 | $0 | $0 | $0 | $0 |
| Judith Gasson | Chair Elect | 1 | $0 | $0 | $0 | $0 |
| Stephanie Lee | Vice Chair | 1 | $0 | $0 | $0 | $0 |
| Robert Soiffer | Secretary | 1 | $0 | $0 | $0 | $0 |
Amy Ronneberg
Chief Executive Officer
$2M
Hrs/Wk
48
Compensation
$1.5M
Related Orgs
$0
Other
$455K
Steven Devine
Chief Medical Officer
$1.1M
Hrs/Wk
50
Compensation
$900.4K
Related Orgs
$0
Other
$219.5K
Krista Dusil
Chief Financial Officer (thru 2/24)
$703K
Hrs/Wk
49
Compensation
$649.8K
Related Orgs
$0
Other
$53.2K
Katherine Heyerdahl
Chief Financial Officer (began 4/24)
$0
Hrs/Wk
48
Compensation
$0
Related Orgs
$0
Other
$0
Brian Reithel
Chair
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Judith Gasson
Chair Elect
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Stephanie Lee
Vice Chair
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Robert Soiffer
Secretary
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Brian Lindberg | Chief Administrative Officer | 49 | $863.5K | $0 | $117.9K | $981.4K |
| Jeffery Auletta | Chief Scientific Director | 49 | $719.4K | $0 | $209.6K | $928.9K |
| Julie Smolich | Svp, Patient & Provider Services | 49 | $690.2K | $0 | $202.1K | $892.4K |
| John Miller | Vp, Medical & Quality Services | 50 | $730.8K | $0 | $106.1K | $836.9K |
| Michael Mccullough | Chief Digital & Information Officer | 47 | $755.3K | $0 | $57K | $812.3K |
Brian Lindberg
Chief Administrative Officer
$981.4K
Hrs/Wk
49
Compensation
$863.5K
Related Orgs
$0
Other
$117.9K
Jeffery Auletta
Chief Scientific Director
$928.9K
Hrs/Wk
49
Compensation
$719.4K
Related Orgs
$0
Other
$209.6K
Julie Smolich
Svp, Patient & Provider Services
$892.4K
Hrs/Wk
49
Compensation
$690.2K
Related Orgs
$0
Other
$202.1K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Anne Mcgeorge | Director | 1 | $0 | $0 | $0 | $0 |
| Elizabeth Shpall | Director | 1 | $0 | $0 | $0 | $0 |
| Garheng Kong | Director | 1 | $0 | $0 | $0 | $0 |
| Laurie Strongin | Director | 1 | $0 | $0 | $0 | $0 |
| Lori Muffly | Director | 1 | $0 | $0 | $0 | $0 |
| Lynn Abrahamsen | Director |
Anne Mcgeorge
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Elizabeth Shpall
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Garheng Kong
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Gina Graves | Former Officer | — | $240K | $0 | $3,353 | $243.3K |
Gina Graves
Former Officer
$243.3K
Hrs/Wk
—
Compensation
$240K
Related Orgs
$0
Other
$3,353
| $50.1M |
| $445.4M |
| $371.7M |
| $235.3M |
| 2019 | $445.4M | $55.3M | $429M | $388.6M | $250.4M |
| 2018 | $418.3M | $53.2M | $406.2M | $365.8M | $231.8M |
| 2017 | $391M | $53.6M | $365.1M | $361.8M | $212.4M |
| 2016 | $392M | $51.1M | $370.5M | $325.2M | $175.4M |
| 2015 | $397.6M | $54.8M | $375.3M | $246.9M | $148.5M |
| 2014 | $383.2M | $51.7M | $368.2M | $266.6M | $135.2M |
| 2013 | $389.3M | $54.9M | $362.8M | $253.5M | $116.9M |
| 2012 | $351.6M | $53.9M | $332.2M | $212.6M | $87.7M |
| 2011 | $316.5M | $44.2M | $303.9M | $197.2M | $65.7M |
| 2021 | 990 | Data |
| 2020 | 990 | Data | PDF not yet published by IRS |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| Erica Jensen |
| Svp, Innovation, Strategy & Marketing |
| 49 |
| $612K |
| $0 |
| $199.9K |
| $811.9K |
| Jamie Margolis | Svp, Donor & Product Operations | 49.5 | $618.6K | $0 | $182.1K | $800.8K |
| Patricia Jones | Svp, Human Resources | 49 | $761.9K | $0 | $11.1K | $773K |
| Joy King | Chief Advancement Officer | 30 | $345.3K | $230.2K | $168.6K | $744.1K |
| Heather Stefanski | Vp, Cibmtr & Clinical Services | 50 | $535.9K | $0 | $111K | $646.9K |
| Mary Hengen | Vp, Cibmtr & Clinical Services | 50 | $484.5K | $0 | $97.4K | $581.9K |
John Miller
Vp, Medical & Quality Services
$836.9K
Hrs/Wk
50
Compensation
$730.8K
Related Orgs
$0
Other
$106.1K
Michael Mccullough
Chief Digital & Information Officer
$812.3K
Hrs/Wk
47
Compensation
$755.3K
Related Orgs
$0
Other
$57K
Erica Jensen
Svp, Innovation, Strategy & Marketing
$811.9K
Hrs/Wk
49
Compensation
$612K
Related Orgs
$0
Other
$199.9K
Jamie Margolis
Svp, Donor & Product Operations
$800.8K
Hrs/Wk
49.5
Compensation
$618.6K
Related Orgs
$0
Other
$182.1K
Patricia Jones
Svp, Human Resources
$773K
Hrs/Wk
49
Compensation
$761.9K
Related Orgs
$0
Other
$11.1K
Joy King
Chief Advancement Officer
$744.1K
Hrs/Wk
30
Compensation
$345.3K
Related Orgs
$230.2K
Other
$168.6K
Heather Stefanski
Vp, Cibmtr & Clinical Services
$646.9K
Hrs/Wk
50
Compensation
$535.9K
Related Orgs
$0
Other
$111K
Mary Hengen
Vp, Cibmtr & Clinical Services
$581.9K
Hrs/Wk
50
Compensation
$484.5K
Related Orgs
$0
Other
$97.4K
| 1 |
| $0 |
| $0 |
| $0 |
| $0 |
| Melinda Caltabiano | Director | 1 | $0 | $0 | $0 | $0 |
| Michael Lang | Director | 1 | $0 | $0 | $0 | $0 |
| Ravyn Miller | Director | 1 | $0 | $0 | $0 | $0 |
| Rayne Rouce | Director | 1 | $0 | $0 | $0 | $0 |
| Uri Herzberg | Director | 1 | $0 | $0 | $0 | $0 |
| Vicki Rasmusen | Director | 1 | $0 | $0 | $0 | $0 |
Laurie Strongin
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Lori Muffly
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Lynn Abrahamsen
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Melinda Caltabiano
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Michael Lang
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Ravyn Miller
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Rayne Rouce
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Uri Herzberg
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Vicki Rasmusen
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0